A Phase II Evaluation of Gemcitabine (Gemzar, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Trial Profile

A Phase II Evaluation of Gemcitabine (Gemzar, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2012

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Endometrial cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 16 Sep 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 03 Mar 2010 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University record no. GOG0129Q).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top